Kazia Therapeutics Announces 100% Clinical Benefit Rate in Advanced Triple-Negative Breast Cancer Trial
Quick Brief
Kazia Therapeutics announced a 100% clinical benefit rate in the first six evaluable patients treated for advanced triple-negative breast cancer. The trial noted a durable complete metabolic response ongoing since November 2025. Furthermore, no treatment-related serious adverse events were observed during the study.
What Happened?
Kazia Therapeutics released initial clinical data for six patients undergoing treatment for advanced triple-negative breast cancer. The results showed a 100% clinical benefit rate alongside a durable complete metabolic response that has been ongoing since November 2025. Additionally, evaluable patients experienced median reductions of 83% in metastasis-associated circulating tumor cell (CTC) clusters and 51% in terminally exhausted T cells, with no treatment-related serious adverse events reported.
Why It Matters
Triple-negative breast cancer is an aggressive form of the disease with limited treatment options. Achieving a 100% clinical benefit rate with no treatment-related serious adverse events in initial patients marks a notable development for Kazia Therapeutics and offers potential promise for advanced-stage cancer therapies.
Key Facts
- Kazia Therapeutics reported a 100% clinical benefit rate in its initial six patients treated for advanced triple-negative breast cancer.
- A durable complete metabolic response has been ongoing since November 2025.
- Patients demonstrated a median reduction of 83% in metastasis-associated CTC clusters.
- A median reduction of 51% in terminally exhausted T cells was also observed.
- No treatment-related serious adverse events were recorded during the evaluation.
